|Articles|April 8, 2022
Daily Medication Pearl: Rabeprazole (AcipHex)
Author(s)Saro Arakelians, PharmD
Rabeprazole (AcipHex) can treat erosive or ulcerative gastroesophageal reflux disease, heartburn, stomach ulcers, and esophageal damage.
Advertisement
Medication Pearl of the Day: AcipHex (Rabeprazole)
Indication: Rabeprazole (AcipHex) is a proton-pump inhibitor (PPI) indicated in adults for healing of erosive or ulcerative gastroesophageal reflux disease (GERD). It can also treat heartburn, stomach ulcers, and esophageal damage.
Insight:
- Dosing: 20 mg to 40 mg every day.
- Dosage forms: Delayed-release tablets: 20 mg, delayed-release capsules: 5 mg and 10 mg.
- Adverse events: In the adult studies (4 to 8 weeks), adverse reactions that occurred at a rate greater than 2% and greater than placebo included pain, pharyngitis, flatulence, infection, and constipation.
- Mechanism of action: Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine.
- Manufacturer: Eisai R&D Management
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
2
Effectively Managing Immunizations in the Long-Term Care Setting
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
5